Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Med Food ; 17(5): 588-98, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24433072

RESUMO

Citric acid is a weak organic acid found in the greatest amounts in citrus fruits. This study examined the effect of citric acid on endotoxin-induced oxidative stress of the brain and liver. Mice were challenged with a single intraperitoneal dose of lipopolysaccharide (LPS; 200 µg/kg). Citric acid was given orally at 1, 2, or 4 g/kg at time of endotoxin injection and mice were euthanized 4 h later. LPS induced oxidative stress in the brain and liver tissue, resulting in marked increase in lipid peroxidation (malondialdehyde [MDA]) and nitrite, while significantly decreasing reduced glutathione, glutathione peroxidase (GPx), and paraoxonase 1 (PON1) activity. Tumor necrosis factor-alpha (TNF-α) showed a pronounced increase in brain tissue after endotoxin injection. The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity. In the liver, nitrite was decreased by 1 g/kg citric acid. GPx activity was increased, while PON1 activity was decreased by citric acid. The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid. DNA fragmentation, however, increased after 4 g/kg citric acid. Thus in this model of systemic inflammation, citric acid (1-2 g/kg) decreased brain lipid peroxidation and inflammation, liver damage, and DNA fragmentation.


Assuntos
Ácido Cítrico/uso terapêutico , Inflamação/tratamento farmacológico , Lipopolissacarídeos/administração & dosagem , Fígado/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Animais , Anti-Inflamatórios , Antioxidantes , Arildialquilfosfatase/análise , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Química Encefálica/efeitos dos fármacos , Caspase 3/análise , Fragmentação do DNA/efeitos dos fármacos , Glutationa Peroxidase/análise , Inflamação/induzido quimicamente , Inflamação/metabolismo , Peroxidação de Lipídeos , Fígado/química , Fígado/efeitos dos fármacos , Hepatopatias/prevenção & controle , Masculino , Camundongos , Óxido Nítrico Sintase Tipo II/análise , Nitritos/análise , Peritônio/efeitos dos fármacos , Fator de Necrose Tumoral alfa/análise
2.
Exp Parasitol ; 122(4): 310-7, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19389399

RESUMO

Schistosomiasis is one of the most important parasitic diseases in Egypt and chemotherapy is considered the most effective method of control. This study was conducted to assess the effectiveness of zinc administration against Schistosoma mansoni infection by evaluating the activities of arylesterase and paraoxonase (PON1) enzymes, and the degree of liver damage. One hundred and twenty albino mice were divided into two groups; one was an infected control and the other a treated group which was further subdivided into three according to the praziquantel and zinc supplementation given. Blood and liver samples, collected 10 weeks post-infection, were subjected to parasitological, histopathological, and enzyme assays, and immunological studies. The results showed that dietary zinc supplementation led to marked reduction in worm load, and egg deposition in the liver and intestine. Histopathological examination showed marked reduction in the number and diameter of hepatic granulomas in the treated groups. The activity of arylesterase and PON1 enzymes were partially restored in infected animals receiving zinc. IL-10 mRNA expression was higher in the treated groups than in the infection control group. In conclusion, zinc administration could be a promising adjuvant therapy for S. mansoni infection.


Assuntos
Anti-Helmínticos/uso terapêutico , Suplementos Nutricionais , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Sulfato de Zinco/administração & dosagem , Animais , Arildialquilfosfatase/análise , Arildialquilfosfatase/sangue , Hidrolases de Éster Carboxílico/análise , Hidrolases de Éster Carboxílico/sangue , Quimioterapia Combinada , Granuloma/tratamento farmacológico , Granuloma/parasitologia , Interleucina-10/genética , Interleucina-10/metabolismo , Fígado/enzimologia , Fígado/parasitologia , Fígado/patologia , Masculino , Camundongos , Óvulo/efeitos dos fármacos , RNA Mensageiro/isolamento & purificação , Schistosoma mansoni/efeitos dos fármacos , Schistosoma mansoni/isolamento & purificação , Esquistossomose mansoni/enzimologia , Esquistossomose mansoni/patologia
3.
Exp Parasitol ; 120(2): 147-55, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18640114

RESUMO

Schistosoma mansoni (S. mansoni) eggs trapped in the host liver elicit a chain of oxidative processes that may be, at least in part, responsible for the pathology and progression of fibrosis associated with schistosomal hepatitis. This study was designed to assess the protective effect of the antioxidant coenzyme-Q10 (Co-Q10) against experimental S. mansoni-induced oxidative stress in the liver, and its potential role as an adjuvant to praziquantel (PZQ) therapy. The oxidative stress and overall liver function were improved under Co-Q10 therapy as evidenced by significant reduction in oxidative stress markers and preservation of antioxidant factors. Liver fibrosis was also reduced with a positive impact on liver function. Moreover, addition of Co-Q10 to PZQ therapy caused: significant reduction of liver egg load, significant improvement of the redox status, and lastly decreased liver fibrosis.


Assuntos
Hepatite/metabolismo , Hepatopatias Parasitárias/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Esquistossomose mansoni/metabolismo , Ubiquinona/farmacologia , Actinas/análise , Animais , Anti-Helmínticos/uso terapêutico , Arildialquilfosfatase/análise , Biomphalaria , Hidrolases de Éster Carboxílico/análise , Modelos Animais de Doenças , Glutationa/análise , Hepatite/tratamento farmacológico , Hepatite/parasitologia , Imuno-Histoquímica , Fígado/química , Fígado/enzimologia , Fígado/parasitologia , Fígado/patologia , Hepatopatias Parasitárias/tratamento farmacológico , Masculino , Malondialdeído/análise , Camundongos , Óxido Nítrico/análise , Contagem de Ovos de Parasitas , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Organismos Livres de Patógenos Específicos , Ubiquinona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA